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1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for fetal growth restriction as an
adverse event following immunization
Fetuses that fail to meet their growth potential in utero are at
risk for adverse antenatal and postnatal events such as stillbirth,
preterm birth, and adverse neonatal and long-term health out-
comes [1–5]. Therefore, antenatal recognition and monitoring of
fetal growth restriction (FGR) is an important component of prena-
tal care [6–8]. Despite the clinical and public health importance of
this problem there is no universally accepted definition of FGR [9–
10]. Furthermore, terminology such as intrauterine growth restric-
tion (IUGR) or small for gestational age (SGA) are used inter-
changeably and without specificity to describe this clinical entity.
In its simplest form, FGR is defined as a sonographic estimation
of fetal weight below the tenth percentile for a given gestational
age [11–14]. Though this definition is simple to understand and
translating into practice, it is an inadequate definition for FGR.FGR can be a consequence of maternal, fetal, or placental fac-
tors. Diagnosing all fetuses with an estimated fetal weight (EFW)
below the tenth percentile with FGR fails to account for the indi-
vidual growth potential of each fetus. Constitutionally small
fetuses who might be expected to have a lower birthweight based
on parental characteristics may be misdiagnosed as pathologically
small [15]. Conversely, fetuses destined for a higher birthweight
may fail to reach their growth potential due to a pathologic process
yet never fall below a threshold based on fetal or birth weight
below a specific centile (e.g. 10th) [16]. An ideal definition of
FGR would detect those fetuses with a pathologic failure to meet
their growth potential subsequently at risk of adverse outcomes.
Numerous studies have attempted to improve the sensitivity
and specificity of the definition through adjunct testing and opti-
mization of growth curves used to define the tenth percentile diag-
nostic cutoff. The sentinel investigations into FGR used
measurements of the fetal head, abdomen, and femur to develop
growth curves within small homogenous patient populations
[17]. Though these measurements yielded reliable estimations of
fetal weight, the growth curves lacked generalizability, particularly
in an international context [18]. Contemporary studies on FGR
have advocated individualized growth curves accounting for
maternal and fetal characteristics such as ethnicity and gender to
solve this dilemma [19–21]. However, large-scale international
prospective studies of healthy pregnancies show little difference
in growth curves between populations [22]. Additional studies
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assessment and use of Doppler attempt to further clarify the defi-
nition of FGR [23,24].
Despite these controversies in defining FGR, its detection is an
important component of antenatal care. The majority of the prior
vaccine studies in pregnant women, including specifically those
focused on obstetric outcomes, do not address FGR as an adverse
outcome [25–28]. Some authors have reported neonatal outcomes
including identification of low birth weight (LBW) and SGA infants
without an attempt to detect these events in pregnancy [29–31].
Though neonatal disorders of growth potential could be considered
a postnatal diagnosis of FGR, they are different diagnoses with dis-
tinct implications within the context of studies on immunizations.
The likely cause of pathologic FGR can vary in according to clin-
ical setting. Some etiologies of FGR, such as preeclampsia or con-
genital anomalies, may be similar across clinical settings. FGR
associated with maternal comorbidity such as advanced maternal
age or gastric bypass surgery can be considered unique to countries
with higher healthcare related expenditures [32,33]. In contrast
FGR in lower income countries is more likely to be associated with
malnutrition or parasitic diseases, with malaria being the classic
example [34–38].
This relationship between maternal infection and FGR is well
described for many diseases—even in the absence of congenital
infection [39–44]. Specifically, FGR has been described as a conse-
quence of vaccine-preventable illnesses, such as influenza [45,46].
As maternal vaccination becomes an increasingly prioritized com-
ponent of routine prenatal care, monitoring for adverse vaccine-
related outcomes gains similar importance. The complex interplay
between FGR, infection, and medical comorbidity makes early
detection and diagnosis of this pregnancy complication of para-
mount importance. Timely diagnosis of a pathologic disorder of
growth potential in utero, as opposed to relying solely on a postna-
tal diagnosis of a pathologically small infant, is necessary to iden-
tify a temporal relationship between the diagnosis of FGR and a
vaccine of interest.
There is a paucity of data on FGR in existing vaccine trials, per-
haps in part due to the controversy surrounding the diagnosis
within the medical community. Given the clinical variation in the
definition, the absence of a uniformly accepted definition of FGR
following immunizations is not surprising. This is, however, a
missed opportunity, as data comparability across trials or surveil-
lance systems would facilitate data interpretation and promote
the scientific understanding of the event.
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for fetal growth
restriction as an adverse events following immunization
Following the process described in the overview paper as well
as on the Brighton Collaboration Website http://www.brightoncol-
laboration.org/internet/en/index/process.html, the Brighton Col-
laboration Fetal Growth Restriction Working Group was formed in
2015 and included members from clinical, academic, public health,
and industry backgrounds [47]. The composition of the working
and reference group as well as results of the web-based survey
completed by the reference group with subsequent discussions in
the working group can be viewed at: http://www.brightoncollabo-
ration.org/internet/en/index/working_groups.html.
To guide the decision-making for the case definition and guideli-
nes, a literature search was performed using Medline, Embase and
the Cochrane Libraries, including the terms [fetal (Fetal) growth
restriction or retardation], [intrauterine growth restriction or retar-
dation] and [small for gestational age]. The search resulted in the
identification of 23,441 English-language references, 5480 of which
were published within the past five years. All abstracts werescreened for relevance to a contemporary definition of FGR in a sin-
gleton pregnancywith particular attention to those related to infec-
tion, immunization, and under-represented countries. 102 articles
with potentially relevant material were reviewed in more detail, in
order to identify studies using case definitions or, in their absence,
providing clinical descriptions of the case material. The literature
search revealed extensive literature on the definition of FGR and
development of associated growth curves and adjunct testing. No
immuzation-related studies contained definitions of FGR and this
outcome was seldom discussed. The most commonly encountered
definitions were in medical society statements and contained sub-
stantial variation in both terminology and definitions. Similar
heterogeneity was found in the definition of FGR throughout scien-
tific studies addressing outcomes and management of this preg-
nancy complication. An inventory comprising the 102 relevant
articles along with society definitions of FGR was made available
to working group members via the Collections feature of MyNCBI.
1.3. Rationale for selected decisions about the case definition of fetal
growth restriction as an adverse event following immunization
1.3.1. The term fetal growth restriction
Terms such as intrauterine growth restriction (IUGR) and small
for gestational age (SGA) are often used in clinical practice inter-
changeably with FGR. The term SGA has been proposed by some
groups, including the Brighton Collaborative, as a diagnosis limited
to neonates [11,48]. Other society guidelines suggest using IUGR
to identify those fetuses at risk of pathologic growth restriction
and limiting the use of SGA to reference a constitutionally small
fetus without evidence of pathology [12–14,49]. In order to distin-
guish between a neonatal and fetal diagnosis of disorders of growth,
use of the term SGA to reference a fetal disorder of growth will be
avoided. IUGRand FGRare used interchangeablywith less confusion
as both clearly reference a diagnosis of growth restriction estab-
lished prior to delivery. To limit confusion between these variably
defined terms the Brighton definitions will utilize the term fetal
growth restriction to define this adverse advent with levels of diag-
nostic certainty to further describe concern for pathologic FGR.
1.3.2. Formulating a case definition that reflects diagnostic certainty:
weighing specificity versus sensitivity
The number of sonographic findings that will be documented
for each case may vary considerably depending on availability of
technology in a given setting and availability of additional clinical
information, such as pregnancy dating, critical to establishing a
diagnosis. The case definition has been formulated such that the
Level 1 definition is highly specific for the condition. As maximum
specificity normally implies a loss of sensitivity, an additional diag-
nostic level has been included in the definition, offering a stepwise
increase of sensitivity from Level 1 to Level 2, while retaining an
acceptable level of specificity at all levels. Each Level has been fur-
ther subdivided into subcategories of A and B in an attempt to bet-
ter define pathologic FGR. Within both Levels, a subgroup of A
provides better specificity and certainty for a pathologic process.
Level B may be more sensitive for FGR but includes less specific
findings with less certainty for its pathology. In this way it is hoped
that all possible cases of FGR can be captured with clarity as to the
concern for a disorder of fetal growth potential.
It needs to be emphasized that the grading of definition levels is
entirely about diagnostic certainty, not clinical severity of an event.
Thus, a clinically very severe event may appropriately be classified
as Level Two rather than Level One if it could reasonably be of non-
FGR etiology (e.g. in cases of limited evidence of pregnancy dating).
Detailed information about the severity of the event should addi-
tionally always be recorded, as specified by the data collection
guidelines.
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case definition
FGR is most often diagnosed by use of ultrasound. Magnetic res-
onance imaging (MRI) of the fetus and placenta shows potential for
furthering understanding of pathophysiology. However, this tech-
nology is time-consuming, expensive, and primarily restricted to
research settings limiting its use for inclusion in the Brighton def-
inition of FGR. At the other end of the spectrum, exam findings
such as symphysis fundal height measurements are clinically ubiq-
uitous for the detection of FGR [50]. This clinical measurement
lacks sensitivity, offers little insight into potential for pathology,
and lacks evidence for routine use limiting its utility in a research
setting [51]. Additional studies such as placental pathologic exam-
ination, placental biomarkers, and related clinical diagnoses may
offer insight into the underlying pathophysiology for FGR [52,53].
This adjunct testing offers clinical utility for screening for and fur-
ther understanding of FGR but lends little to establishing the initial
diagnosis. Therefore, the Brighton case definition of FGR will focus
on use of a combination of B-mode and Doppler ultrasound tech-
nology to establish the diagnosis of FGR. This approach should
allow for adequate sensitivity and specificity without making iden-
tification of the adverse event overly cumbersome for investigators
in study settings with limited resources. Ultrasound may not be
universally available in all clinical settings, but its presence is req-
uisite for diagnosis of FGR as an adverse event within the context
of vaccine trials. In settings where ultrasound is unavailable for
an antenatal diagnosis of disorders of fetal growth, investigators
may use the Brighton Definition for Small for Gestational Age neo-
nates as an alternative [48].
The most basic definition of FGR includes a fetus with a sono-
graphic estimation of fetal weight below the tenth percentile for
a given gestational age with increasing specificity for adverse peri-
natal outcomes below the third percentile [24]. A variety of fetal
biometric measurements and functional Doppler studies have been
studied to optimize the detection of FGR. Biometric parameters
typically involve an assessment of head size (e.g. biparietal diame-
ter (BPD), head circumference (HC), occipitofrontal diameter
(OFD)), abdominal size (e.g. abdominal circumference (AC) or
abdominal diameter (AD)), and femur length [54,55]. A compre-
hensive guide to the technical performance of these measurements
and other sonographic technique is beyond the scope of this paper,
but several key points must be emphasized. Healthcare providers
performing obstetric ultrasound should be trained in proper tech-
nique with assessment of quality to ensure inter- and intra-rater
reliability. Selected sonographic studies should follow interna-
tional published standards for obtaining and reporting measure-
ments with appropriate references to resources used during
scientific publication.
As previously described, the choice of a specific growth curve
and its associated characteristics is a subject of ongoing debate
in the obstetric community based on wide variation between pub-
lished reference curves [18]. Many publically available growth
curves currently available in ultrasound machines were derived
from small homogenous populations [17]. Customized growth
curves incorporating maternal and fetal characteristics have shown
improved specificity over population-based curves in individual
studies yet fail to demonstrate superiority in the most recent
meta-analyses [19,21,56]. Contemporary population-based growth
curves derived from a diverse population of low-risk pregnancies
such as those from the INTERGROWTH-21st package show little
variation in fetal size across non-isolated populations [22,57,58].
Yet translation of these growth standards into clinical practice is
ongoing with presumably limited access to this data in existing
technology [59]. The majority of existing society guidelines either
lack recommendations on specific growth curve use or suggest
employing a customized curve [12,14,49]. However, all of theseguidelines were developed before the recent publication of newer
fetal growth standards and expert opinion varies [10,60,61].
Resolving the ongoing debate of the ideal growth curve selec-
tion is beyond the scope of this project. Furthermore, prescribing
a specific standard may unduly restrict participation of study sites
with limited resources to access additional growth curves. Though
the Brighton definition of FGR does not include a single specific
growth curve, several key features of a selected growth curve
should be emphasized. Study sites in any given trial should select
a single curve to allow for meaningful comparison between sites.
Selected growth curves should be internationally validated using
a large sample size and published as a peer-reviewed study with
an available reference. An optimal curve would be based on preg-
nancies with reliable early pregnancy dating, prospective data col-
lection, and validation of measurements to avoid intra-observer
bias.
In addition to a sonographic estimation of fetal weight, addi-
tional techniques can be used to aid in the diagnosis of FGR. As
with the acquisition of measurements, adherence to existing per-
formance standards should be ensured when performing this
adjunctive testing [62]. These additional studies can include an
assessment of amniotic fluid volume and Doppler velocities
through varying maternal, placental, and fetal vessels where tech-
nology allows. Amongst the variety of Doppler studies available,
assessment of velocities in the umbilical artery is one of the most
accessible both in terms of technical ease and interpretation.
Absence or reversal of diastolic velocities in the umbilical artery
has been associated with adverse perinatal outcomes that are rare
in the setting of normal umbilical artery velocities [63]. Inclusion
of umbilical artery Doppler waveforms in the definition allows
for added certainty in the diagnosis of pathologic growth restric-
tion with minimal additional time or skill.
Doppler studies of the middle cerebral artery (MCA), ductus
venosus, uterine arteries and the relationships between these val-
ues (e.g. the cerebral placental ratio (CPR)) have also been
employed in the clinical description and prediction of FGR. Con-
temporary expert consensus guidelines attempting to better char-
acterize early-onset and late-onset FGR underscore the clinical
utility of measurements such as the CPR and the umbilical artery
pulsatility index (PI) in assessment of FGR [60]. The PI is calculated
using the peak systolic velocity, end diastolic velocity, and time
averaged velocity in a given artery and comparing this value to
existing standards for a given gestational age. An umbilical artery
PI above the 95%ile has been associated with adverse perinatal out-
comes similar to absent or reversed diastolic frequencies but with
lower incidence [24]. This clinically useful measurement would
likely improve the specificity of pathologic growth restriction,
but has a slightly greater technical requirement with a need for
further interpretation using a normative standard. The working
group balanced specificity for FGR with establishing a case defini-
tion that can be achieved across a wide range of clinical settings
with varying access to equipment and operator training. For this
reason, pulsatility indices were not included in the case definition
of FGR.
Similar reasoning guided the exclusion of CPR in the group’s
definition of FGR. The CPR is derived by comparing the PI in the
umbilical artery to that in the MCA and has a similar role in pre-
dicting adverse outcomes likely due to its role in detecting brain-
sparing growth restriction [64,65]. Brain-sparing growth restric-
tion in which a fetus redirects blood flow away from the viscera
in favor of the brain is associated with poorer perinatal outcomes
[66]. Aside from an abnormal CPR, this subset of FGR is suggested
by an abdominal circumference lagging the estimated weight of
the fetus [24]. An isolated abdominal circumference below the
tenth percentile can be associated with adverse outcomes and
has been utilized in recent consensus guidelines to define pathol-
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have similar variation and challenges to those involving estimated
fetal weight and rely on a single measurement to define pathology
[18]. Though assessment for brain-sparing using these techniques
would add specificity to the pathologic FGR diagnosis, it would
involve significant additional technical requirements as well as
increase the risk of false positives due to technical error. Based
on this information and the absence of recommendation for rou-
tine use in existing clinical guidelines use of Doppler other than
velocimetry in the umbilical artery are not included in the case def-
inition for FGR [23,24].
Assessment of amniotic fluid volume is a routine component of
prenatal ultrasound and diagnosis with varying definitions of
oligohydramnios in the literature. Potential etiologies for oligohy-
dramnios are diverse and this finding is less specific than Doppler
velocities in predicting adverse perinatal outcomes [24]. In the
absence of evidence of rupture of membranes or fetal anomalies
contributing to the pathology, oligohydramnios is often inter-
preted as a marker for placental insufficiency and therefore pathol-
ogy. Though an estimated fetal weight below the tenth percentile
in association with oligohydramnios does not predict adverse out-
comes, it does suggest pathologic FGR more so than an isolated
finding of a small fetus. Therefore, in an attempt to improve the
sensitivity of the case definition for FGR oligohydramnios has been
included in the definition realizing it may decrease specificity.
Additional sensitivity in the definition could be achieved by
tracking an individual fetus’s growth over time. Serial ultrasound
would improve sensitivity for FGR through identification of fetuses
failing to reach their growth potential but not falling below the
tenth percentile. The improvement in sensitivity would come at a
tradeoff for additional ultrasound scans which may be overly cum-
bersome in the context of a vaccine trial. In the interest of feasibil-
ity these criteria were not included in the case definition.
The current case definition balances sensitivity and specificity
of the definition of FGR. However great care was taken to consider
the feasibility of the definition within the context of a vaccine trial
with the potential for study sites with varying access to healthcare
resources and technology. Access to basic B-mode ultrasound is
requisite for the diagnosis at any level of certainty, with a require-
ment for basic Doppler capabilities for the highest level of diagnos-
tic certainty. In an attempt to make a Level One diagnosis of FGR
accessible, after thoughtful consideration more complex criteria
that could improve the sensitivity or specificity of detection of dis-
orders of fetal growth potential were excluded.
1.3.4. Timing post immunization
Specific time frames for onset of symptoms following immu-
nization are not included in the definition of FGR. There is a paucity
of data about relationship between immunization and FGR with no
evidence on which to base recommendations on a temporal rela-
tionship. We postulate that a definition designed to be a suitable
tool for testing causal relationships requires ascertainment of the
outcome (e.g. FGR) independent from the exposure (e.g. immu-
nizations). Therefore, to avoid selection bias, a restrictive time
interval from immunization to onset of FGR should not be an inte-
gral part of such a definition. Instead, where feasible, details of this
interval should be assessed and reported as described in the data
collection guidelines.
Further, FGR often occurs outside the controlled setting of a
clinical trial or hospital. When possible, a sonographic assessment
of fetal weight before vaccination could aid in the evaluation of
FGR prior to vaccine administration. In cases where FGR can be
identified prior to vaccine administration exclusion of these preg-
nancies from the trial can be considered. Given the increase in
adverse events in pregnancies affected by FGR this strategy mayavoid an overestimation of associations between the vaccine and
an adverse outcome. In some settings it may be impossible to
screen for FGR or obtain a clear timeline of the event, particularly
in less developed or rural settings. In order to avoid selecting
against such cases, the Brighton Collaboration case definition
avoids setting requirements for FGR screening and arbitrary time
frames.
1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case definition is
accompanied by guidelines which are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis
and presentation. Neither case definition nor guidelines are
intended to guide or establish criteria for management of ill
infants, children, or adults. Both were developed to improve data
comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of fetal growth restriction
2.1. For all levels of diagnostic certainty
Fetal growth restriction is a sonographic finding characterized
by:
Level 1 of diagnostic certainty
Level 1a
Level 1⁄ evidence of pregnancy dating [67].
AND
Estimated fetal weight below 3% using locally-accepted growth
curve.
OR
Estimated fetal weight below 10% using locally-accepted
growth curve.AND
Absent or reversed end-diastolic flow of the umbilical artery
Doppler.
OR
Oligohydramnios.y
Level 1b
Level 1⁄ evidence of pregnancy dating [67].
AND
Estimated fetal weight below 10%ile using locally-accepted
growth curve
AND
Lack of absent or reversed end-diastolic flow of the umbilical
artery or oligohydramnios.y
Level 2 of diagnostic certainty
Level 2a
Level 2 evidence of pregnancy dating [67].
AND
Estimated fetal weight below 3% using locally-accepted growth
curve
OR
Estimated fetal below 10% using locally-accepted growth curveAND
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Doppler.
OR
Oligohydramniosy
Level 2b
Level 2 evidence of pregnancy dating [67].
AND
Estimated fetal weight below 10%ile using locally-accepted
growth curve
AND
No findings of absent or reversed end-diastolic flow of the
umbilical artery or oligohydramniosy.
OR
Level 1⁄ evidence of pregnancy dating [67].
AND
Estimated fetal weight below 10% using locally-accepted
growth curve with no findings of oligohydramniosy with inabil-
ity to assess umbilical artery Doppler.
2.2. Insufficient evidence
Absence of ultrasound for use in assessment of estimated fetal
weight.
*Level 1 evidence of pregnancy dating as defined by the Preterm
Birth Working Group of the Brighton Collaboration. Level 1 preg-
nancy dating depends on a confirmatory ultrasound performed
613 6/7 weeks gestation [67].
yOligohydramnios is defined as a decreased amniotic fluid vol-
ume as defined by amniotic fluid index less than 8 cm or deepest
vertical pocket less than 2 cm in the presence of intact membranes
without concern for fetal anomalies contributing to its etiology.
When compared to umbilical artery Dopplers, oligohydramnios
lacks specificity for pathologic placental underperfusion and lacks
association with adverse perinatal outcomes [24]. It is, however, a
useful sonographic findings in situations lacking access to Doppler
ultrasound and often impacts clinical management of pregnancies
with suspected FGR despite its lack of specificity.3 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.3. Guidelines for data collection, analysis and presentation of
fetal growth restriction
It was the consensus of the Brighton Collaboration Fetal Growth
Restriction Working Group to recommend the following guidelines
to enable meaningful and standardized collection, analysis, and
presentation of information about FGR. However, implementation
of all guidelines might not be possible in all settings. The availabil-
ity of information may vary depending upon resources, geograph-
ical region, and whether the source of information is a prospective
clinical trial, a post-marketing surveillance or epidemiological
study, or an individual report of FGR. Also, as explained in more
detail in the overview paper in this volume, these guidelines have
been developed by this working group for guidance only, and are
not to be considered a mandatory requirement for data collection,
analysis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following immunization to allow for
comparability of data, and are recommended as an addition to data
collected for the specific study question and setting. The guidelines
are not intended to guide the primary reporting of FGR to a surveil-
lance system or study monitor. Investigators developing a data col-
lection tool based on these data collection guidelines also need torefer to the criteria in the case definition, which are not repeated in
these guidelines.
Guidelines 1–42 below have been developed to address data
elements for the collection of adverse event information as speci-
fied in general drug safety guidelines by the International Confer-
ence on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use, and the form for
reporting of drug adverse events by the Council for International
Organizations of Medical Sciences [68,69]. These data elements
include an identifiable reporter and patient, one or more prior
immunizations, and a detailed description of the adverse event,
in this case, of FGR following immunization. The additional guide-
lines have been developed as guidance for the collection of addi-
tional information to allow for a more comprehensive
understanding of FGR following immunization.3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting3 and/or
diagnosing the FGR as specified by country-specific data pro-
tection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g., immunizer [clinician, nurse],
family member [indicate relationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight.3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(8) Past medical history, including hospitalizations, underlying
diseases/disorders with careful identification as to their
presence in the mother or fetus, pre-immunization signs
and symptoms including identification of indicators for, or
the absence of, a history of allergy to vaccines, vaccine com-
ponents or medications; food allergy; allergic rhinitis;
eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long term
effect. (e.g. immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)), in particular
occurrence of FGR after a previous immunization.
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For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.), diluent name, and
number of dose if part of a series of immunizations against
the same disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Sonographic findings of FGR and if there was medical confir-
mation of the event (i.e. patient seen or images reviewed by
physician).
(18) Date/time of onset,4 first observation5 and diagnosis,6 end of
episode7 and final outcome.8
(19) Concurrent signs, symptoms, and diseases.9
(20) Measurement/testing4 The
first sig
determi
5 The
for FGR
6 The
met the
7 The
definitio
8 E.g.
peutic i
9 An
the foll
inpatien
results
birth de Values and units of routinely measured parameters (e.g.
measurements, amniotic fluid volume, umbilical artery
Doppler studies, additional Doppler studies) – in particu-
lar those indicating the severity of the event;
 Method of measurement (e.g. type of ultrasound, partic-
ular growth curve or references used);
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.(21) Follow up given for FGR, especially follow up monitoring
(e.g. repeat ultrasounds or other assessments of fetal well-
being) and delivery planning.
(22) Outcome8 at last observation.
(23) Exposures other than the immunization 24 h before and
after immunization (e.g. food, environmental) considered
potentially relevant to the reported event.
3.1.5. Miscellaneous/general
(24) The duration of surveillance for FGR should be predefined
based ondate and/or time of onset is defined as the time post immunization, when the
n or symptom indicative for FGR occurred. This may only be possible to
ne in retrospect.
date and/or time of first observation of the first sign or symptom indicative
can be used if date/time of onset is not known.
date of diagnosis of an episode is the day post immunization when the event
case definition at any level.
end of an episode is defined as the time the event no longer meets the case
n at the lowest level of the definition.
recovery to pre-immunization health status, spontaneous resolution, thera-
ntervention, persistence of the event, sequelae, death.
AEFI is defined as serious by international standards if it meets one or more of
owing criteria: (1) it results in death, (2) is life-threatening, (3) it requires
t hospitalization or results in prolongation of existing hospitalization, (4)
in persistent or significant disability/incapacity, (5) is a congenital anomaly/
fect, (6) is a medically important event or reaction.
10 To d
reporte
certaint
definitio
diagnos
approac
given ev
should
the eve
11 If t
missing
evidenc Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
 Biologic characteristics of the vaccine-targeted disease;
 Biologic characteristics of FGR including patterns identi-
fied in previous trials (e.g. early-phase trials); and
 Biologic characteristics of the vaccinee (e.g. nutrition,
underlying disease like immunodepressing illness).
(25) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(26) Methods of data collection should be consistent within and
between study groups, if applicable.
(27) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1 to 23.
(28) Investigators of patients with FGR should provide guidance
to reporters to optimize the quality and completeness of
information provided.
(29) Reports of FGR should be collected throughout the study
period regardless of the time elapsed between immuniza-
tion and the adverse event. If this is not feasible due to the
study design, the study periods during which safety data
are being collected should be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on FGR to allow for comparability of data, and
are recommended as an addition to data analyzed for the specific
study question and setting.
(30) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 4 categories10
Event meets case definition
(1) Level 1: Criteria as specified in the Fetal Growth Restric-
tion case definition
(2) Level 2: Criteria as specified in the Fetal Growth Restric-
tion case definitionEvent does not meet case definition
Additional categories for analysis(1) Reported FGR with insufficient evidence to meet the case
definition11
(2) Not a case of FGR
(31) The interval between immunization and reported FGR could
be defined as the date/time of immunization to the date/
time of onset4 of the first symptoms and/or signs consistentetermine the appropriate category, the user should first establish, whether a
d event meets the criteria for the lowest applicable level of diagnostic
y, e.g. Level Two B. If the lowest applicable level of diagnostic certainty of the
n is met, and there is evidence that the criteria of the next higher level of
tic certainty are met, the event should be classified in the next category. This
h should be continued until the highest level of diagnostic certainty for a
ent could be determined. If the lowest level of the case definition is not met, it
be ruled out that any of the higher levels of diagnostic certainty are met and
nt should be classified in additional categories three or four.
he evidence available for an event is insufficient because information is
, such an event should be categorized as ‘‘Reported FGR with insufficient
e to meet the case definition”.
6552 S.R. Easter et al. / Vaccine 35 (2017) 6546–6554with the definition. If few cases are reported, the concrete
time course could be analyzed for each; for a large number
of cases, data can be analyzed in the following increments:
Subjects with Fetal Growth Restriction by Interval to
PresentationInterval⁄ Number
0 – <2 weeks after immunization
2 – <4 weeks after immunization
4 – <8 weeks after immunization
8 – <12 weeks after immunization
Week increments thereafter
TOTAL
12 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of FGR”.
13 Use of this document should preferably be referenced by referring to the
respective link on the Brighton Collaboration website (http://www.brightoncollabo-
ration.org).(32) The duration of a possible FGR could be analyzed as the
interval between the date/time of onset3 of the first sono-
graphic findings consistent with the definition and the end
of diagnosis7 and/or final outcome.8 Whatever start and end-
ing are used, they should be used consistently within and
across study groups.
(33) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(34) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases
are presented, the respective values or time course can be
presented individually.
(35) Data on FGR obtained from subjects receiving a vaccine
should be compared with those obtained from an appropri-
ately selected and documented control group(s) to assess
background rates of FGR in non-exposed populations, and
should be analyzed by study arm and dose where possible,
e.g. in prospective clinical trials [47].
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on FGR following immunization to
allow for comparability of data, and are recommended as an addi-
tion to data presented for the specific study question and setting.
Additionally, it is recommended to refer to existing general guide-
lines for the presentation and publication of randomized controlled
trials, systematic reviews, and meta-analyses of observational
studies in epidemiology (e.g. statements of Consolidated Standards
of Reporting Trials (CONSORT), of Improving the quality of reports
of meta-analyses of randomized controlled trials (QUORUM), and
of meta-analysis Of Observational Studies in Epidemiology
(MOOSE), respectively) [70–72].
(36) All reported events of FGR should be presented according to
the categories listed in guideline 30.
(37) Data on possible FGR events should be presented in accor-
dance with data collection guidelines 1–23 and data analysis
guidelines 30–35.
(38) Terms to describe FGR such as ‘‘low-grade”, ‘‘mild”, ‘‘moder-
ate”, ‘‘high”, ‘‘severe” ‘‘significant”, ‘‘early onset”, ‘‘late
onset”, ‘‘asymmetric”, ‘‘symmetric” are highly subjective,
prone to wide interpretation, and should be avoided, unless
clearly defined.(39) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomi-
nator data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
(40) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(41) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(42) Any publication of data on FGR should include a detailed
description of the methods used for data collection and anal-
ysis as possible. It is essential to specify:
(43) The study design;
 The method of pregnancy dating;
 The method, frequency and duration of monitoring for
FGR;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The type of surveillance (e.g. passive or active
surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The validated instrument of data collection (e.g. stan-
dardized questionnaire, diary card, report form);
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset4 and/or the date of first obser-
vation5 and/or the date of diagnosis6 was used for analy-
sis; and12
 Use of this case definition for FGR, in the abstract or
methods section of a publication.13Disclaimer
The findings, opinions and assertions contained in this consen-
sus document are those of the individual scientific professional
members of the working group. They do not necessarily represent
the official positions of each participant’s organization (e.g., gov-
ernment, university, or corporation). Specifically, the findings and
conclusions in this paper are those of the authors and do not nec-
essarily represent the views of their respective institutions.
Acknowledgements
The authors are grateful for the support and helpful comments
provided by the Brighton Collaboration and the reference group
(see https://brightoncollaboration.org/public/what-we-do/
S.R. Easter et al. / Vaccine 35 (2017) 6546–6554 6553setting-standards/case-definitions/groups.html for reviewers), as
well as other experts consulted as part of the process. The authors
are also grateful to Jan Bonhoeffer, Jorgen Bauwens of the Brighton
Collaboration Secretariat and Sonali Kochhar of Global Healthcare
Consulting for final revisions of the final document. Finally, we
would like to acknowledge the Global Alignment of Immunization
Safety Assessment in Pregnancy (GAIA) project, funded by the Bill
and Melinda Gates Foundation.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2017.01.
042.
References
[1] Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal
risk factors for stillbirth: population based study. BMJ 2013;24(346):f108.
[2] Pilliod RA, Cheng YW, Snowden JM, Doss AE, Caughey AB. The risk of
intrauterine fetal death in the small-for-gestational-age fetus. Am J Obstet
Gynecol 2012;207(4):318e1–6.
[3] von Beckerath AK, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P.
Perinatal complications and long-term neurodevelopmental outcome of
infants with intrauterine growth restriction. Am J Obstet Gynecol 2013;208
(2):130e1–6.
[4] Lees C, Marlow N, Arabin B, Bilardo CM, Brezinka C, Derks JB, et al. Perinatal
morbidity and mortality in early-onset fetal growth restriction: cohort
outcomes of the trial of randomized umbilical and fetal flow in Europe
(TRUFFLE). Ultrasound Obstet Gynecol 2013;42(4):400–8.
[5] Lees CC, Marlow N, van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka
C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in
infants with very preterm fetal growth restriction (TRUFFLE): a randomised
trial. Lancet 2015;385(9983):2162–72.
[6] Gardosi J, Giddings S, Buller S, Southam M, Williams M. Preventing stillbirths
through improved antenatal recognition of pregnancies at risk due to growth
restriction. Public Health 2014;128(8):698–702.
[7] Imdad A, Yakoob MY, Siddiqui S, Bhutta ZA. Screening and triage of
intrauterine growth restriction (IUGR) in general population and high risk
pregnancies: a systematic review with a focus on reduction of IUGR related
stillbirths. BMC Public Health 2011;11(Suppl 3):S1.
[8] Sovio U, White IR, Dacey A, Pasupathy D, Smith GC. Screening for fetal growth
restriction with universal third trimester ultrasonography in nulliparous
women in the Pregnancy Outcome Prediction (POP) study: a prospective
cohort study. Lancet 2015;386(10008):2089–97.
[9] Chauhan SP, Gupta LM, Hendrix NW, Berghella V. Intrauterine growth
restriction: comparison of American College of Obstetricians and
Gynecologists practice bulletin with other national guidelines. Am J Obstet
Gynecol 2009;200(4). 409e1–6.
[10] Unterscheider J, O’Donoghue K, Malone FD. Guidelines on fetal growth
restriction: a comparison of recent national publications. Am J Perinatol
2015;32(4):307–16.
[11] ACOG Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol. 2013
May;121(5):1122-33.
[12] Green-top guidelines. London, UK: Royal College of Obstetricians and
Gynaecologists; 2013. Available on the world wide web: https://www.rcog.
org.uk/globalassets/documents/guidelines/gtg_31.pdf [last accessed January
16, 2016].
[13] Lausman A, McCarthy FP, Walker M, Kingdom J. Screening, diagnosis, and
management of intrauterine growth restriction. J Obstet Gynaecol Can
2012;34(1):17–28.
[14] Vayssiere C, Sentilhes L, Ego A, Bernard C, Cambourieu D, Flamant C, et al. Fetal
growth restriction and intra-uterine growth restriction: guidelines for clinical
practice from the French College of Gynaecologists and Obstetricians. Eur J
Obstet Gynecol Reprod Biol 2015;193:10–8.
[15] Ananth CV, Vintzileos AM. Distinguishing pathological from constitutional
small for gestational age births in population-based studies. Early Hum Dev
2009 Oct;85(10):653–8.
[16] Barker ED, McAuliffe FM, Alderdice F, Unterscheider J, Daly S, Geary MP, et al.
The role of growth trajectories in classifying fetal growth restriction. Obstet
Gynecol 2013;122(2 Pt 1):248–54.
[17] Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal
weight with the use of head, body, and femur measurements—a prospective
study. Am J Obstet Gynecol 1985;151:333–7.
[18] Ioannou C, Talbot K, Ohuma E, Sarris I, Villar J, Conde-Agudelo A, et al.
Systematic review of methodology used in ultrasound studies aimed at
creating charts of fetal size. BJOG 2012;119:1425–39.
[19] Gardosi J, Francis A. A customized standard to assess fetal growth in a US
population. Am J Obstet Gynecol 2009;201(25):e1–7.[20] Gardosi J, Clausson B, Francis A. The value of customized centiles in assessing
perinatal mortality risk associated with parity and maternal size. BJOG
2009;116:1356–63.
[21] Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gülmezoglu AM, et al. A
global reference for fetal-weight and birthweight percentiles. Lancet 2011;377
(9780):1855–61.
[22] Papageorghiou AT, Ohuma EO, Altman DG, Todros T, Cheikh Ismail L, Lambert
A, et alInternational Fetal and Newborn Growth Consortium for the 21st
Century (INTERGROWTH-21st). International standards for fetal growth based
on serial ultrasound measurements: the Fetal Growth Longitudinal Study of
the INTERGROWTH-21st Project. Lancet 2014;384(9946):869–79.
[23] Society for Maternal-Fetal Medicine Publications Committee, Berkley E,
Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine
growth restriction. Am J Obstet Gynecol 2012;206(4):300–8.
[24] Unterscheider J, Daly S, Geary MP, Kennelly MM, McAuliffe FM, O’Donoghue K,
et al. Optimizing the definition of intrauterine growth restriction: the
multicenter prospective PORTO Study. Am J Obstet Gynecol 2013;208(4).
290e1–6.
[25] Moro PL, Broder K, Zheteyeva Y, Revzina N, Tepper N, Kissin D, et al. Adverse
events following administration to pregnant women of influenza A (H1N1)
2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting
System. Am J Obstet Gynecol 2011;205(5). 473e1–9.
[26] Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC,
Naleway A, et al. Evaluation of the association of maternal pertussis
vaccination with obstetric events and birth outcomes. JAMA 2014;312
(18):1897–904.
[27] Morgan JL, Baggari SR, McIntire DD, Sheffield JS. Pregnancy outcomes after
antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstet
Gynecol 2015;125(6):1433–8.
[28] Sukumaran L, McCarthy NL, Kharbanda EO, McNeil MM, Naleway AL, Klein NP,
et al. Association of Tdap vaccination with acute events and adverse birth
outcomes among pregnant women with prior tetanus-containing
immunizations. JAMA 2015;314(15):1581–7.
[29] Källén B, Olausson PO. Vaccination against H1N1 influenza with Pandemrix
during pregnancy and delivery outcome: a Swedish register study. BJOG
2012;119(13):1583–90.
[30] Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD,
Melbye M, et al. Risk of adverse fetal outcomes following administration of a
pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 2012;308
(2):165–74.
[31] Nordin JD, Kharbanda EO, Vazquez Benitez G, Lipkind H, Vellozzi C, Destefano
F. Vaccine safety datalink. Maternal influenza vaccine and risks for preterm or
small for gestational age birth. J Pediatr 2014;164(5):1051–7.
[32] Zapata-Masias Y, Marqueta B, Gomez Roig MD, Gonzalez-Bosquet E. Obstetric
and perinatal outcomes in women >40 years or age: associations with fetal
growth disorders. Early Hum Dev 2016;100:17–20.
[33] Parker MH, Berghella V, Nijjar JB. Bariatric surgery and associated adverse
pregnancy outcomes among obese women. J Matern Fetal Neonatal Med
2016;29(11):1747–50.
[34] Landis SH, Lokomba V, Ananth CV, Atibu J, Ryder RW, Hartmann KE, et al.
Impact of maternal malaria and under-nutrition on intrauterine growth
restriction: a prospective ultrasound study in Democratic Republic of Congo.
Epidemiol Infect 2009;137(2):294–304.
[35] Unger HW, Ome-Kaius M, Karl S, Singirok D, Siba P, Walker J, et al. Factors
associated with ultrasound-aided detection of suboptimal fetal growth in a
malaria-endemic area of Papua New Guinea. BMC Pregnancy Childbirth
2015;3(15):83.
[36] Schmiegelow C, Minja D, Oesterholt M, Pehrson C, Suhrs HE, Bostrom S, et al.
Malaria and fetal growth alterations in the 3(rd) trimester of pregnancy: a
longitudinal ultrasound study. PLoS ONE 2013;8(1):e53794.
[37] Machado Filho AC, da Costa EP, da Costa EP, Reis IS, Fernandes EA, Paim BV,
et al. Effects of vivax malaria acquired before 20 weeks of pregnancy on
subsequent changes in fetal growth. Am J Trop Med Hyg 2014;90(2):371–6.
[38] Rijken MJ, Papageorghiou AT, Thiptharakun S, Kiricharoen S, Dwell SL,
Wiladphaingern J, et al. Ultrasound evidence of early fetal growth restriction
after maternal malaria infection. PLoS ONE 2012;7(2):e31411.
[39] Huang QT, Hang LL, Zhong M, Gao YF, LuoML, Yu YH. Maternal HCV infection is
associated with intrauterine fetal growth disturbance: a meta-analysis of
observational studies. Medicine 2016;95(35):e4777.
[40] Wanyama R, Kagawa MN, Opio KC, Baingana RK. Effect of maternal
Helicobacter Pylori infection on birth weight in an urban community in
Uganda. BMC Pregnancy Childbirth 2016;16(1):158.
[41] Yudin MH, Caprara D, MacGillivray SJ, Urquia M, Shah RR. A ten-year review of
antenatal complications and pregnancy outcomes among HIV-positive
pregnant women. J Obstet Gynaecol Can 2016;38(2):35–40.
[42] Olagbuji BN, Ezeanochie MC, Ande AB, Oboro VO. Obstetric and perinatal
outcome in HIV positive women receiving HAART in urban Nigeria. Arch
Gynecol Obstet 2010;281(6):991–4.
[43] Cailhol J, Jourdain G, Coeur SL, Traisthit P, Boonrod K, Prommas S, et al.
Prevention Trial Group. Association of low CD4 cell count and intrauterine
growth retardation in Thailand. J Acquir Immune Defic Syndr 2009;50
(4):409–13.
[44] American College of Obstetricians and Gynecologists, Practice Bulletin No. 151.
Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in
pregnancy. Obstet Gynecol 2015;125(6):1510–25.
6554 S.R. Easter et al. / Vaccine 35 (2017) 6546–6554[45] Steinhoff MC, Omer SB. A review of fetal and infant protection associated with
antenatal influenza immunization. Am J Obstet Gynecol 2012;207(3 Suppl):
S21–7.
[46] Centers for Disease Control and Prevention (CDC). Maternal and infant
outcomes among severely ill pregnant and postpartum women with 2009
pandemic influenza A (H1N1)–United States, April 2009–August 2010. MMWR
Morb Mortal Wkly Rep 2011;60(35):1193–6.
[47] Jones CE, Munoz FM, Spiegel HM, Heininger U, Zuber PL, et al. Guideline for
collection, analysis, and presentation of safety data in clinical trials of vaccines
in pregnant women. Vaccine 2016. pii: S0264–410X(16)30615–6.
[48] Schlaudecker EP, Munoz FM, Bardaji A, Boghossian NS, Khalil A, Mousa H, et al.
Small for gestational age: case definition & guidelines for data collection,
analysis, and presentation of maternal immunisation safety data. Vaccine
2017;35(48):6710–6720.
[49] Clinical Practice Guideline Fetal Growth Restriction—Definition, Diagnosis and
Management. Institute of Obstetricians and Gynaecologists, Royal College of
Physicians of Ireland and Directorate of Clinical Strategy and Programmes,
Health Service Executive; 2013. Available on the world wide web: https://
www.hse.ie/eng/about/Who/clinical/natclinprog/obsandgynaeprogramme/
guidelines/fetal.pdf [last accessed January 16, 2016].
[50] Sparks TN, Cheng YW, McLaughlin B, Esakoff TF, Caughey AB. Fundal height: a
useful screening tool for fetal growth? J Matern Fetal Neonatal Med 2011;24
(5):708–12.
[51] Robert Peter J, Ho JJ, Valliapan J, Sivasangari S. Symphysial fundal height (SFH)
measurement in pregnancy for detecting abnormal fetal growth. Cochrane
Database Syst Rev 2015;9:CD008136.
[52] Mifsud W, Sebire NJ. Placental pathology in early-onset and late-onset fetal
growth restriction. Fetal Diagn Ther 2014;36(2):117–28.
[53] Odibo AO, Patel KR, Spitalnik A, Odibo L, Huettner P. Placental pathology, first-
trimester biomarkers and adverse pregnancy outcomes. J Perinatol 2014;34
(3):186–91.
[54] American Institute of Ultrasound in Medicine. AIUM practice guideline for the
performance of obstetric ultrasound examinations. J Ultrasound Med 2013;32
(6):1083–101.
[55] Papageorghiou AT, Sarris I, Ioannou C, Todros T, Carvalho M, Pilu G,
et alInternational Fetal and Newborn Growth Consortium for the 21st
Century. Ultrasound methodology used to construct the fetal growth
standards in the INTERGROWTH 21st Project. BJOG 2013;120(Suppl 2):27–32.
[56] Carberry AE, Gordon A, Bond DM, Hyett J, Raynes-Greenow CH, Jeffery HE.
Customised versus population-based growth charts as a screening tool for
detecting small for gestational age infants in low-risk pregnant women.
Cochrane Database Syst Rev 2014(5):CD008549.
[57] Villar J, Papageorghiou AT, Pang R, Ohuma EO, Cheikh Ismail L, Barros FC,
et alInternational Fetal and Newborn Growth Consortium for the 21st Century.
The likeness of fetal growth and newborn size across non-isolated populations
in the INTERGRWOTH-21st Project: the fetal growth longitudinal study and
newborn cross-sectional study. Lancet Diabetes Endocrinol 2014;2
(10):781–92.
[58] Anderson NH, Sadler LC, McKinlay CJ, McCowan LM. INTERGROWTH-21st vs
customized birthweight standards for identification of perinatal mortality. Am
J Obstet Gynecol 2016;214(4). 509e1–7.
[59] Chatfield A, Caglia JM, Dhillon S, Hirst J, Cheikh Ismail L, Abawi L,
et alInternational Fetal and Newborn Growth Consortium for the 21stCentury. Translating research into practice: the introduction of the
INTERGROWTH-21st package of clinical standards, tools and guidelines into
policies, programmes, and clinical services. BJOG 2013;120(Suppl 2):139–42.
[60] Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN,
et al. Consensus definition for placental fetal growth restriction: a Delphi
procedure. Ultrasound Obstet Gynecol 2016.
[61] Unterscheider J, Daly S, Gear MP, Kennelly MM, McAuliffe FM, O’Donoghue K,
et al. Definition and management of fetal growth restriction: a survey of
contemporary attitudes. Eur J Obstet Gynecol Reprod Biol 2014;174:41–5.
[62] Nicolaides K, Rizzo G, Hecher K, Ximenes R. Doppler in Obstetrics—The Fetal
Medicine Foundation. Accessed on the world wide web: https://fetalmedicine.
org/var/uploads/Doppler-in-Obstetrics.pdf [last accessed June 26, 2016].
[63] O’Dwyer V, Burke G, Unterscheider J, Daly S, Geary MP, Kennelly MM, et al.
Defining the residual risk of adverse perinatal outcome in growth-restricted
fetuses with normal umbilical artery blood flow. Am J Obstet Gynecol
2014;211(4). 420e1–5.
[64] Khalil AA, Morales-Rosello J, Morlando M, Hannan H, Bhide A, Papageorghiou
A, et al. Is fetal cerebroplacental ration an independent predictor of
intrapartum fetal compromise and neonatal unit admission? Am J Obstet
Gynecol 2015;213(1). 54e1–10.
[65] Khalil AA, Morales-Rosello J, Elsaddig M, Khan N, Papageorghiou A, Bhide A,
et al. The association between fetal Doppler and admission to neonatal unit at
term. Am J Obstet Gynecol 2015;213(1). 57e1–7.
[66] Flood K, Unterscheider J, Daly S, Geary MP, Kennelly MM, McAuliffe FM, et al.
The role of brain sparing in the prediction of adverse outcomes in intrauterine
growth restriction: results of the multicenter PORTO Study. Am J Obstet
Gynecol 2014;211(3). 288e1–5.
[67] Quinn JA, Munoz FM, Gonick B, Frau L, Cutland C, Mallett-Moore T, et al.
Preterm birth: case definition and guidelines for data collection, analysis, and
presentation of immunization safety data. Vaccine 2016;34(49):6047–56.
[68] International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH). Guidelines for Clinical
Safety assessment (E2a–e). Available on the world wide web: http://www.ich.
org/ [last accessed: April 14, 2016].
[69] Council for International Organizations of Medical Sciences (CIOMS).
Reporting form for International Reporting of Adverse Drug Reactions.
Available on the world wide web: http://www.cioms.ch/frame what is
cioms.htm [last accessed: April 14, 2016].
[70] The CONSORT statement: revised recommendations for improving the quality
of reports of parallel-group randomized trials. JAMA 2001;285(15):1987–91.
Available on the world wide web: http://www.consort-statement.org/
Statement/revisedstatement.htm [last accessed: April 14, 2016]..
[71] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the
quality of reports of meta-analyses of randomised controlled trials: the
QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354
(9193):1896–900. Available on the world wide web: http://www.consort-
statement.org/Initiatives/complements.htm [last accessed: April 14, 2016]..
[72] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-
analysis of observational studies in epidemiology: a proposal for reporting.
Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA
2000;283(15):2008–12. Available on the world wide web: http://
www.consort-statement. org/Initiatives/complements.htm [last accessed:
April 14, 2016]..
